Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer (vol 18, pg 758, 2012)

被引：0
|
作者：
Sun, Jessica D.
Liu, Qian
Wang, Jingli
Ahluwalia, Dharmendra
Ferraro, Damien
Wang, Yan
Duan, Jian-Xin
Ammons, W. Steve
Curd, John G.
Matteucci, Mark D.
Hart, Charles P.
机构：
来源：
CLINICAL CANCER RESEARCH | 2024年 / 30卷 / 10期
关键词：
D O I：
10.1158/1078-0432.CCR-24-1058
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2287 / 2287
页数：1
相关论文
共 50 条
  • [1] Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
    Sun, Jessica D.
    Liu, Qian
    Wang, Jingli
    Ahluwalia, Dharmendra
    Ferraro, Damien
    Wang, Yan
    Duan, Jian-Xin
    Ammons, W. Steve
    Curd, John G.
    Matteucci, Mark D.
    Hart, Charles P.
    CLINICAL CANCER RESEARCH, 2012, 18 (03) : 758 - 770
  • [2] TH-302: bench to bedside with a tumor-selective hypoxia-activated prodrug for lung cancer
    Weiss, Glen J.
    Borad, Mitesh J.
    Chiorean, Elena G.
    Mita, Alain C.
    Langmuir, Virginia K.
    Kroll, Stewart
    Hart, Charles P.
    Sun, Jessica D.
    Meng Fanying
    Infante, Jeffrey R.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S385 - S385
  • [3] The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
    Li, Yue
    Zhao, Long
    Li, Xiao-Feng
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [4] Hypoxia-activated prodrug TH-302 enhances antitumor activity of antiangiogenics in preclinical models
    Sun, Jessica D.
    Ahluwalia, Dharmendra
    Liu, Qian
    Wang, Yan
    Meng, Fanying
    Bhupathi, Deepthi
    Curd, John G.
    Matteucci, Mark D.
    Hart, Charles P.
    CANCER RESEARCH, 2011, 71
  • [5] Efficacy of the hypoxia-activated prodrug TH-302 in a preclinical model of prostate cancer metastasis
    Hart, Charles P.
    Sun, Jessica
    Liu, Qian
    Ammons, W. S.
    Lister, Deanne
    McConville, Patrick
    Matteucci, Mark
    CLINICAL & EXPERIMENTAL METASTASIS, 2009, 26 (07) : 851 - 852
  • [6] Preclinical dose sequence and regimen optimization of the hypoxia-activated prodrug TH-302
    Sun, Jessica
    Liu, Qian
    Ahluwalia, Dharmendra
    Ferraro, Damien
    Wang, Yan
    Henjarappa, Nirupama
    Curd, John
    Matteucci, Mark
    Hart, Charles
    CANCER RESEARCH, 2009, 69
  • [7] Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models
    Portwood, Scott
    Lal, Deepika
    Hsu, Yung-Chun
    Vargas, Rodrigo
    Johnson, Megan K.
    Wetzler, Meir
    Hart, Charles P.
    Wang, Eunice S.
    CLINICAL CANCER RESEARCH, 2013, 19 (23) : 6506 - 6519
  • [8] Bench to bedside experience with TH-302: A tumor-selective hypoxia-activated prodrug as a promising treatment for prostate cancer
    Hart, Charles P.
    Armstrong, Andrew J.
    Chiorean, Elena G.
    Sun, Jessica D.
    Langmuir, Virginia K.
    Meng, Fanying
    Eng, Clarence
    Kroll, Stewart
    Matteucci, Mark D.
    Curd, John G.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [9] Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302
    Lohse, Ines
    Rasowski, Joanna
    Cao, Pinjiang
    Pintilie, Melania
    Do, Trevor
    Tsao, Ming-Sound
    Hill, Richard P.
    Hedley, David W.
    ONCOTARGET, 2016, 7 (23) : 33571 - 33580
  • [10] Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug
    Hu, Jinsong
    Handisides, Damian R.
    Van Valckenborgh, Els
    De Raeve, Hendrik
    Menu, Eline
    Broek, Isabelle Vande
    Liu, Qian
    Sun, Jessica D.
    Van Camp, Ben
    Hart, Charles P.
    Vanderkerken, Karin
    BLOOD, 2010, 116 (09) : 1524 - 1527
12345